文献速递头颈部肿瘤放疗乳腺癌放疗姑息放疗与转移瘤

局部应用氨磷汀代谢物温敏凝胶预防放射性损伤

Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-05-04

研究开发了含氨磷汀活性硫醇代谢物CPh-1014的温敏凝胶,在体表或黏膜局部涂抹。小鼠模型显示,照射前应用CPh-1014可显著减轻单次或分次照射所致的口腔黏膜炎和皮炎严重程度,减少照射上皮DNA双链断裂,且不影响移植瘤的放疗疗效;犬实验显示口服应用CPh-1014未诱发低血压。

要点

  • CPh-1014温敏凝胶局部应用可减轻小鼠放射性口腔黏膜炎和皮炎。
  • CPh-1014减少照射上皮DNA双链断裂,且不影响移植瘤放疗疗效。
  • 犬口服CPh-1014未诱发低血压,有别于静脉氨磷汀。

核心结论

  • CPh-1014在健康组织中提供放射保护作用,全身副作用减少,且不损害放疗疗效。
  • 作者提出CPh-1014可作为易于实施的疗法,减轻乳腺癌和头颈癌患者的放疗毒性。

研究设计与样本

  • 研究为临床前动物实验,开发了含氨磷汀活性硫醇代谢物CPh-1014的温敏凝胶,体温下聚合作为局部涂抹于皮肤或黏膜的基质。
  • 在体小鼠模型接受单次或分次照射,评估CPh-1014照射前应用对口腔黏膜炎和皮炎的影响。
  • 在犬中评估口服应用CPh-1014对血压的影响。

主要发现

  • 照射前应用CPh-1014大幅降低小鼠单次或分次照射所致口腔黏膜炎和皮炎的严重程度。
  • CPh-1014的细胞保护作用经照射上皮DNA双链断裂减少所证实。
  • CPh-1014不影响黏膜下和皮下移植瘤的放疗疗效。
  • 与静脉给予氨磷汀不同,犬口服CPh-1014未诱发低血压。

临床怎么用

  • 对于乳腺癌和头颈癌放疗患者,可考虑局部涂抹CPh-1014温敏凝胶以预防或减轻放射性皮炎和口腔黏膜炎。
  • CPh-1014局部应用可能避免静脉氨磷汀相关的低血压、恶心、呕吐等全身不良反应及给药不便。
  • 使用CPh-1014进行放射保护时,无需担心其削弱对黏膜下和皮下移植瘤的放疗疗效。

局限性

  • 证据主要来自小鼠和犬的临床前实验,尚未在患者中验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite the development of high-precision radiation therapy, ionizing radiation inevitably damages healthy tissues. Radiodermatitis and radioinduced oral mucositis are frequent and significant side effects among patients with breast and head and neck cancer, respectively. These radiation-related injuries negatively affect patient quality of life and can lead to unplanned therapeutic breaks and compromise treatment outcomes. Currently, no preventive or mitigating agent has emerged to address these issues. Although amifostine, a well-known free radical scavenger, has proven efficacy against specific radio- and chemo-induced toxicities, severe adverse side effects (reversible hypotension, nausea, emesis, etc) combined with logistical hurdles are associated with its recommended intravenous route of administration, limiting its use. METHODS AND MATERIALS: We developed a thermogel containing the active thiol metabolite of amifostine (CPh-1014) that polymerizes at body temperature and serves as a matrix for topical application onto the skin or mucosa. RESULTS: Applied before irradiation, CPh-1014 greatly reduced the severity of oral mucositis and dermatitis induced by either a single dose or fractionated irradiation regimens in in vivo mouse models. The cytoprotective effect of CPh-1014 was confirmed by the decrease in DNA double-strand breaks in the irradiated epithelium. Noticeably, CPh-1014 did not affect radiation therapy efficacy against tumors grafted at submucosal and subcutaneous sites. In contrast to the intravenous administration of amifostine, CPh-1014 oral application did not induce hypotension in dogs. CONCLUSIONS: CPh-1014 confers radioprotective effects in healthy tissues with reduced systemic side effects without compromising radiation therapy efficacy. We propose CPh-1014 as an easy-to-implement therapeutic approach to alleviate radiation therapy toxicity in patients with breast and head and neck cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Clémenson C, Liu W, Bricout D, et al. Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel. Int J Radiat Oncol Biol Phys. 2019. PMID: 31063799. doi:10.1016/j.ijrobp.2019.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。